Corcept Therapeutics (CORT)CFO sold ~$67K

~$67K

Approx. value · 600 sh @ $110.95

80K

Holds after · shares reported

Traded

Jul 30, 2026

Filed

Aug 4, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jun 1, 2026Insider · 3 peopleInsiders: 4 sales (~$5.5M)
2. Jun 2, 2026InsiderOfficer sold ~$1.41M of CORT shares in the open market
3. Jun 15, 2026Insider · 1 personInsiders: 4 sales (~$3.2M)
4. Jun 16, 2026Insider · 1 personInsiders: 2 sales (~$832K)
5. Jun 17, 2026InsiderDirector sold ~$1.69M of CORT shares in the open market
6. Jul 1, 2026Insider · 1 personInsiders: 3 sales (~$2.2M)
7. Jul 7, 2026Insider · 1 personInsiders: 2 sales (~$1.9M)
8. Jul 15, 2026Insider · 2 peopleInsiders: 8 sales (~$4.4M)
9. Jul 29, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
10. Jul 30, 2026 · this disclosureInsiderCFO sold ~$67K of CORT shares in the open market

What came next

1. Jul 30, 2026Insider · 1 personInsiders: 12 sales (~$9.1M)
2. Aug 3, 2026Insider · 2 peopleInsiders: 2 sales (~$2.5M)
3. Aug 4, 2026InsiderOfficer sold ~$419K of CORT shares in the open market
4. Aug 10, 2026Insider · 2 peopleInsiders: 3 sales (~$2.0M)
5. Aug 14, 2026Insider · 2 peopleInsiders: 4 sales (~$1.5M)
6. Aug 17, 2026InsiderOfficer sold ~$1.16M of CORT shares in the open market
7. Aug 18, 2026Insider · 1 personInsiders: 4 sales (~$12.3M)
8. Aug 25, 2026Insider · 1 personInsiders: 2 sales (~$3.9M)
9. Aug 26, 2026InsiderDirector sold ~$3.27M of CORT shares in the open market
10. Sep 1, 2026Insider · 1 personInsiders: 3 sales (~$2.9M)
11. Sep 2, 2026Insider · 1 personInsiders: 7 sales (~$6.5M)
12. Sep 14, 2026Insider · 1 personInsiders: 2 sales (~$1.1M)
13. Sep 15, 2026Insider · 1 personInsiders: 3 sales (~$1.1M)
14. Sep 16, 2026InsiderOfficer sold ~$30K of CORT shares in the open market
15. Sep 22, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On September 22, 2026, Sean Maduck, the President of Corcept Endocrinology, notified the Board of Directors of Corcept Therapeutics Incorporated (the “Company”) of his decision to resign effective as of October 1, 2026.”
16. Oct 1, 2026Insider · 2 peopleInsiders: 2 sales (~$141K)
17. Oct 2, 2026Insider · 3 peopleInsiders: 6 sales (~$3.1M)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Corcept Therapeutics

For Corcept Therapeutics, OQRO holds 64 insider filings (SEC Form 4 or Form 144) and 5 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CORT page.

Other recent filings by Atabak Mokari, Chief Financial Officer

• SEC Form 4 at Corcept Therapeutics (CORT)Aug 4, 2026
• SEC Form 4 at Corcept Therapeutics (CORT)Aug 4, 2026
• SEC Form 4 at Corcept Therapeutics (CORT)Aug 4, 2026
• SEC Form 4 at Corcept Therapeutics (CORT)Aug 4, 2026
• SEC Form 4 at Corcept Therapeutics (CORT)Aug 4, 2026

The full history of Atabak Mokari, Chief Financial Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Corcept Therapeutics

• SEC Form 4Oct 6, 2026
• SEC Form 4Oct 6, 2026
• SEC Form 4Oct 6, 2026
• SEC Form 4Oct 6, 2026
• SEC Form 4Oct 6, 2026
• SEC Form 4Oct 6, 2026

Everything OQRO holds on this company is on its CORT page.